

Special Issue

Small Extracellular Vesicles: A Novel Avenue for Brain Tumor Management 2.0

Message from the Guest Editors

The purpose of this Special Issue is to attract articles (both original research articles and reviews) from experts in the field of EV research in the brain tumor that can take innovative approaches or express novel views on the multifaceted world of EVs in cancer biology, progression and therapy. We invite the colleagues to focus on the small EVs, which has been widely demonstrated to mediate transfer of several bioactive molecules including miRNA. Original papers and review articles that focus on the latest advances in small EV studies for brain tumor management are welcome. Key areas that will be covered in this Special Issue include the following:

- The use of model systems to study the biology of small EVs in brain tumors and their use for theranostic approaches;
- The relations between the cells of origin and their targets;
- The use of EVs as a source of candidate biomarkers for liquid biopsy;
- The role of EVs in inflammation and shaping of the brain tumor microenvironment;
- The characterization of specific cargos and their role in recipient cells and cancer progression;
- The EV engineering for design of targeted therapy strategies.

Guest Editors

Dr. Ingrid Cifola

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

Dr. Igea D'Agnano

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/133113

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).